These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22771238)

  • 1. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder.
    Adler LA; Kroon RA; Stein M; Shahid M; Tarazi FI; Szegedi A; Schipper J; Cazorla P
    Biol Psychiatry; 2012 Dec; 72(11):971-7. PubMed ID: 22771238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial.
    Nations KR; Dogterom P; Bursi R; Schipper J; Greenwald S; Zraket D; Gertsik L; Johnstone J; Lee A; Pande Y; Ruigt G; Ereshefsky L
    J Psychopharmacol; 2012 Dec; 26(12):1525-39. PubMed ID: 22954616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
    Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
    Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
    J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
    Herring WJ; Wilens TE; Adler LA; Baranak C; Liu K; Snavely DB; Lines CR; Michelson D
    J Clin Psychiatry; 2012 Jul; 73(7):e891-8. PubMed ID: 22901359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
    Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
    J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD.
    Rivkin A; Alexander RC; Knighton J; Hutson PH; Wang XJ; Snavely DB; Rosah T; Watt AP; Reimherr FW; Adler LA
    J Atten Disord; 2012 Nov; 16(8):664-74. PubMed ID: 22090395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.